Invitae Corporation's ability to collect accounts receivable sequentially worsen to 5.51, indicating more challenging environment then in the second quarter 2023, but still, it is a far cry from any concerns. Average collection period, for Invitae's accounts receivable remained unchanged at 66 days, in the Sep 30 2023 quarter.

If we take a look into Healthcare sector 375 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2023 from 2576 to 2581.

What is Receivable Turnover Ratio?
What is Invitae Corporation Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NVTA Receivables Turnover Ratio	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter
Y / Y Receivable Change	-7.43 %	3.66 %	6.46 %	45.18 %	52.54 %
Y / Y Revenue Change	-9.21 %	-11.78 %	-5.12 %	-2.91 %	16.73 %
Receivable Turnover Ratio (TTM)	5.51	5.54	5.77	5.93	6.53
NVTA's Total Ranking	# 2581	# 2576	# 2525	# 2525	# 2558
Accounts Receivable average collection period days	66	66	63	62	56
Seq. Receivable Change	-3.62 %	0.02 %	-10.98 %	7.87 %	7.92 %
Seq. Revenue Change	0.59 %	2.71 %	-4.16 %	-8.3 %	-2.26 %

Receivable Turnover Company Ranking
Within:	No.
Medical Laboratories Industry	# 21
Healthcare Sector	# 376
Overall Market	# 2581

Receivable Turnover Ratio Statistics
High	Average	Low
0.58	0.29	0.1
(Dec 31 2018)		(Mar 31 2022)

NVTA Company Profile • Back to NVTA Efficiency Comparisons • Compare NVTA Receivables Turnover Ratio to its Competitors

Financial Statements
Invitae's Accounts Receivable	$ 83 Millions	Visit NVTA's Balance sheet
Invitae's Sales TTM	$ 482 Millions	Visit NVTA's Income Statement
Sources of NVTA's Revenues		Visit NVTA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Laboratories Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NVTA's Receivable Turnover Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NVTA's Growth Rates	NVTA's Roa	NVTA's Inventory Turnover Ratio	NVTA's Dividend Comparisons
NVTA's Profitability Ratios	NVTA's Roi	NVTA's Asset Turnover Ratio	NVTA's Dividend Growth
NVTA's Valuation Ratios	NVTA's Roe	NVTA's Financial Strength Ratios	NVTA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2023, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2023	Receivable at quarter ending Sep 30 2023
Opus Genetics Inc	15.89	$ 57.208 Millions	$ 3.600 Millions
Lftd Partners Inc	15.79	$ 49.404 Millions	$ 3.129 Millions
Chemed Corporation	15.30	$ 2,225.159 Millions	$ 145.392 Millions
Vystar Corporation	15.28	$ 0.417 Millions	$ 0.027 Millions
Patterson Companies Inc	14.56	$ 6,550.083 Millions	$ 449.864 Millions
Talkspace Inc	14.24	$ 137.071 Millions	$ 9.623 Millions
Ainos Inc	14.15	$ 1.140 Millions	$ 0.081 Millions
Comera Life Sciences Holdings Inc	14.07	$ 1.000 Millions	$ 0.071 Millions
Lifeloc Technologies Inc	14.00	$ 9.250 Millions	$ 0.661 Millions
Nexalin Technology Inc	13.80	$ 0.129 Millions	$ 0.009 Millions
Corcept Therapeutics Inc	13.76	$ 450.026 Millions	$ 32.698 Millions
Protalix Biotherapeutics inc	13.48	$ 63.625 Millions	$ 4.719 Millions
Exact Sciences Corporation	13.42	$ 2,413.259 Millions	$ 179.784 Millions
Arrowhead Pharmaceuticals Inc	13.36	$ 240.735 Millions	$ 18.023 Millions
Petvivo Holdings Inc	13.14	$ 0.960 Millions	$ 0.073 Millions
Icu Medical Inc	13.12	$ 2,247.910 Millions	$ 171.300 Millions
Milestone Scientific Inc	13.11	$ 9.788 Millions	$ 0.747 Millions
Dmk Pharmaceuticals Corporation	12.53	$ 3.525 Millions	$ 0.281 Millions
Utah Medical Products Inc	12.49	$ 51.339 Millions	$ 4.112 Millions
Ideaya Biosciences Inc	12.46	$ 23.484 Millions	$ 1.886 Millions
Nutriband Inc	12.45	$ 2.088 Millions	$ 0.168 Millions
Precipio inc	12.45	$ 13.259 Millions	$ 1.065 Millions
Revance Therapeutics Inc	12.38	$ 214.162 Millions	$ 17.292 Millions
Equillium Inc	12.38	$ 42.632 Millions	$ 3.444 Millions
Amylyx Pharmaceuticals Inc	12.30	$ 294.222 Millions	$ 23.922 Millions
Caribou Biosciences Inc	12.19	$ 34.611 Millions	$ 2.840 Millions
Strata Critical Medical Inc	12.18	$ 215.837 Millions	$ 17.726 Millions
Teladoc Health Inc	12.17	$ 2,579.597 Millions	$ 211.896 Millions
Reflect Scientific Inc	12.16	$ 1.370 Millions	$ 0.113 Millions
International Stem Cell Corporation	12.16	$ 8.330 Millions	$ 0.685 Millions

Date modified: 2026-09-08T15:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.